Walgreens in talks for private equity buyout, sources say

Walgreens is currently in talks to take the company private, with sources familiar with the matter telling the Wall Street Journal the retailer could be sold to a private equity firm. 

According to report, Walgreens and Sycamore partners have taken an interest in the struggling pharmacy chain. A deal could be completed in early  2025, assuming the parties come to an agreement. 

Walgreens has been rattled by poor sales. In June, the company said 25% of its stores were struggling and that it planned to shutter many of them as it worked to restructure its business. 

At that time, the company said it still believed it would turn a profit in 2024. Judging by its latest financial statements, it appears that’s still the case. However, sales have been sliding for several years

The company has also been embroiled in legal battles, settling an opioid prescription complaint with the city government of Baltimore for $80 million in September. That same month, it paid out $107 million to resolve accusations of Medicare and Medicaid fraud brought by the U.S. Department of Justice. 

It settled another fraud lawsuit in November related to its prescription membership program, paying a class-action of plaintiffs $100 million.

Walgreens stock has slidden downward over 52% since December last year. It did not see any upward turn on news that it may be selling to private equity—however, sources said investors are thrilled by the news. 

The potential sale to Sycamore Partners seems like a good match. The New York-based firm has a history of investing in the consumer retail space, with a portfolio that includes Staples, Belk and Hot Topic. 

Walgreens currently operates around 8,700 stores in the U.S. and 12,000 globally. 

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.” 

The FDA recently cleared the company's cable-free, credit card-sized heart monitor that produces 12-lead ECGs.